Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients

Ipsen SA

28/05/2026 06:32

May 28 (Reuters) - Ipsen SA IPN.PA:
IQIRVO SHOWS CLINICALLY MEANINGFUL FATIGUE IMPROVEMENTS IN MODERATE-TO-SEVERE PBC PATIENTS
IQIRVO ACHIEVES 59% ALP NORMALIZATION AT 6 MONTHS IN REAL-WORLD PBC ANALYSIS
ELFINITY PHASE IV INTERIM ANALYSIS SHOWS REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF IQIRVO
Source text: ID:nGNX7VS7yh
Further company coverage: IPN.PA

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;;))